Key points from article :
EnClear Therapies announced a $10 million Series A financing for a therapy to turn into a clinical trial.
Company’s first products are targeted for patients with ALS and Progressive Supranuclear Palsy.
New therapy assumes fast diagnosis and delivery of any drug directly into the cerebrospinal fluid.
Technology clears toxic proteins from the brain, spinal fluids of ALS patients with the C9orf72 mutation.
Aim is to develop the technology into a device that will recirculate the brain and spinal fluids.
